Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: Follow-up of a randomised clinical trial of transdermal nicotine patch

Pharmacogenomics Journal

Volumn 8, Issue 2, 2008, Pages 122-128

  David, S P ^a   Munafo M R ^b   Murphy, M F G ^c   Proctor, M ^c   Walton, R T ^c,d   Johnstone, E C ^c  

^a MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE; DOPAMINE 4 RECEPTOR; NICOTINE PATCH; PLACEBO; THYMINE;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NICOTINE REPLACEMENT THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RISK FACTOR; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT DURATION; VARIABLE NUMBER OF TANDEM REPEAT;

ADMINISTRATION, CUTANEOUS; ADULT; DOUBLE-BLIND METHOD; EUROPEAN CONTINENTAL ANCESTRY GROUP; EXONS; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MINISATELLITE REPEATS; NICOTINE; NICOTINIC AGONISTS; ODDS RATIO; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE D4; RISK ASSESSMENT; RISK FACTORS; SMOKING; SMOKING CESSATION; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 40949133385     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500447     Document Type: Article

References (66)

1. Peto R, Lopez AD, Boreham J, Thun M, Heath CJ, Doll R. Mortality from. smoking worldwide. Br Med Bull 1996; 52: 12-21.
2. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: Combination of national statistics with two case-control studies. BMJ 2000; 321: 323-329.
3. Heath AC, Cates R, Martin NG, Meyer J, Hewitt JK, Neale MC et al. Genetic contribution to risk of smoking initiation: Comparisons across birth cohorts and across cultures. J Subst Abuse 1993; 5: 221-246.
4. Li MD, Cheng R, Ma JZ, Swan GE. A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction 2003; 98: 23-31.
5. Madden PA, Heath AC, Pedersen NL, Kaprio J, Koskenvuo MJ, Martin NG. The genetics of smoking persistence in men and women: A multicultural study. Behav Genet 1999; 29: 423-431.
6. True WR, Heath AC, Scherrer JF, Waterman B, Goldberg J, Lin N et al Genetic and environmental contributions to smoking. Addiction 1997; 92: 1277-1287.
7. Lerman C, Niaura R. Applying genetic approaches to the treatment of nicotine dependence. Oncogene 2002; 21: 7412-7420.
8. Balfour DJ. Neuroplasticity within the mesoaccumbens dopamine system and its role in tobacco dependence. Curr Drug Targets CNS Neurol Disord 2002; 1: 413-421.
9. Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol 2000; 393: 295-314.
10. Benwell ME, Balfour DJ. The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity. Br J Pharmacol 1992; 105: 949-856.
11. Corrigall WA, Coen KM, Adamson KL. Self-administered nicotine activates the mesolimbic dopamine system through the ventral terental area. Brain Res 1994; 653: 278-284.
12. Epping-Jordan MP, Watkins SS, Koob GF, Markou A. Dramatic decreases in brain reward function during nicotine Withdrawal. Nature 1998; 393: 76-79.
13. Koob GF, Le Moal M. Drug abuse: Hedonic homeostatic dysregulation: Science 1997; 278: 52-58.
14. Munafo M, Clark T, Johnstone E, Murphy M, Walton R. The genetic basis for smoking behavior a systematic review and meta-analysis. Nicotine Tob Res 2004; 6: 583-597.
15. Johnstone EC, Yudkin PL, Hey K, Roberts SJ, Welch SJ, Murphy MF et al Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 2004; 14 83-90.
16. Lerman C, Jepson C, Wileyto EP, Epstein LH, Rukstalis M, Patterson F et al. Role of functional genetic variation in the doparnine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: Results of two randomized clinical trials. Neuropsychopharmocology 2006; 31: 231-242.
17. Yudkin P, Munafo M, Hey K, Roberts S, Welch S, Johnstoni E et al. Effectiveness of nicotine patches in relation to genotype in women versus men: Randomised controlled trial. BMJ 2004; 328: 989-990.
18. David SP, Brown RA, Papandonatos CD, Lloyd-Richardson EE, Munafo' MR, Shields PG et al. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res 2007; 9: (in press).
19. Lerman C, Shields PG, Wileyto EP, Audrain J, Hawk Jr LH, Pinto A et al. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 2003; 22: 541-548.
20. Swan GE, Valdes AM, Ring HZ, Khroyan TV, Jack LM, Ton CC et al. Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics 12005; 5: 21-29.
21. Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat 2004; 23: 540-545.
22. Rivera A, Cuellar B, Giron FJ, Grandy DK, de la Calle A, Moratalla R. Dopamine D4 receptors are heterogeneously distributed in the striosomes/ matrix compartments of the striatum. J Neurochem 2002; 80: 219-229.
23. Gelernter J, Kennedy JL, van Tol HH, Civelli O, Kidd KK. The D4 dopamine receptor (DRD4) maps to distal 11p close to HRAS. Genomics 1992; 13: 208-210.
24. Asghari V, Schoots O, van Kats S, Ohara K, Jovanovic V, Guan HC et al Dopamine D4 receptor repeat: Analysis of different native and mutant forms of the human and rat genes. Mol Pharmacol 1994; 46: 364-373.
25. Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic dozapine. Nature 1991; 350: 610-614.
26. Van Tol HH, Wu CM, Guan HC, Ohara K, Bunzow JR, Civelli O et al. Multiple clopamine D4 receptor variants in the human population. Nature 1992; 358: 149-152.
27. Asghari V, Sanyal S, Buchwaldt S, Paterson A, Jovanovic V, Van Tol HH. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem 1995; 65: 1157-1165.
28. Comings DE, Gonzalez N, Wu S, Gade R, Muhleman D, Saucier G et al. Studies of the 48 bp repeat polymorphism of the DRD4 gene in impulsive, compulsive, addictive behaviors: Togrette syndrome, ADHD, pathological gambling, and substance abuse. Am Med Genet 1999; 88: 358-368.
29. Faraone SV, Doyle AE, Mick E, Biederman J. Meta-analysis of the association between the 7-repeat allele of the dopamine D(4) receptor gene and attention deficit hyperattivity disorder. Am J Psychiatry 2001; 158: 1052-1057.
30. LaHoste GJ, Swanson JM, Wigal SB, Glabe C, Wigal T, King N et al. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol Psychiatry 1996; 1: 121-124.
31. Mill JS, Caspi A, McClay J, Sugden K, Purcell S, Asherson P et al. The dopamine D4 receptor and the hyperactivity phenotype: Developmental - epidemiological study. Mol Psychiatry 2002; 7: 383-391.
32. Muglia P, Jain U, Macciardi F, Kennedy JL. Adult attention deficit hyperactivity disorder and the dopamine D4 receptor gene. Am J Med Genet 2000; 96: 273-277.
33. Rowe DC, Stever C, Giedinghagen LN, Gard JM, Cleveland HH, Terris ST et al. Dopamine DRD4 receptor polymorphism and attention deficit hyperactivity disorder. Mol Psychiatry 1998; 3: 419-426.
34. Swanson JM, Sunohara GA, Kennedy JL, Regina R, Fineberg E, Wigal T et al. Association bf the dopamine receptor D4 (DRD4) gene with a refined phenotype of attention deficit hyperactivity disorder (ADHD): A family-based approach. Mol Psychiatry 1998; 3: 38-41.
35. Munafo MR, Clark TG, Moore LR, Payne E, Walton R, Flint J. Genetic polymorphisms and personality in healthy adults: A systematic review and meta-analysis. Mol Psychiatry 2003; 8: 471-484.
36. Benjamin J., Li. L, Patterson C, Greenberg BD, Murphy DL, Hamer DH. Population and familial association between the D4 dopamine receptor gene and measures of Novelty Seeking. Nat Genet 1996; 12: 81-84.
37. Ebstein RP, Novick O, Umansky R, Priel B, Osher Y, Blaine D et al. Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of Novelty Seeking. Nat Genet 1996; 12 78-80.
38. Ebstein RP, Segman R, Benjamin J, Osher Y, Nimahov L, Belmaker RH. 5-HT2C (HTR2C) serotonin receptor gene polymorphism associated with the human personality trait of reward dependence: Interaction with dopamine D4 receptor (D4DR) ind dopamine D3 receptor (D3DR) polymorphisms. Am J Med Genet 1997; 74: 65-72.
39. Gelemter J, Kranzler R, Coccaro E, Siever L, New A, Mulgrew CL. D4 dopamine-receptor (DRD4) alleles and novelty seeking in substance-dependent, personality-disorder, and control subjects. Am J Hum Genet 1997; 61: 1144-1152.
40. Malhotra AK, Virkkunen M, Rooney W, Eggert M, Linnolla M, Goldman D. The association between the dopamine D4 receptor (D4DR) 16 amino acid repeat polymorphism and novelty seeking. Mol Psychiatry 1996; 1: 388-391.
41. Ono Y, Manki H, Yoshimura K, Muramatsu T, Mizushima H, Higuchi S et al. Association between dopamine D4 receptor (D4DR) exon III polymorphism and novelty seeking in Japanese subjects. Am J Med Genet 1997; 74: 501-503.
42. Ronai Z, Szekely A, Nemoda Z, Lakatos K, Gervai J, Staub M et al. Association between Novelty Seeking and the -521 C/T polymorphism in the promoter region of the DRD4 gene. Mol Psychiatry 2001; 6: 35-38.
43. Sander T, Harms H, Dufeu P, Kuhn S, Rommel spacher H, Schmidt LG. Dopamine D4 receptor exon III alleles and variation of novelty seeking in alcoholics. Am J Med Genet 1997; 74: 483-487.
44. Fan J, Fossella J, Sommer T, Wu Y, Posner MI. Mapping the genetic variation of executive attention onto brain activity. Proc Natl Acad Sci USA 2003; 100: 7406-7411.
45. Lerman C, Caporaso N, Main D, Audrain J, Boyd NR, Bowman ED et al. Depression and self-medicatioh with nicotine: The modifying influence of the dopamine D4 receptor gene. Health Psychol 1998; 17: 56-62.
46. Shields PG, Lerman C, Audrain J, Bowman ED, Main D, Boyd NR et al. Dopamine D4 receptors and the risk of cigarette smoking in African-Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 1998; 7: 453-458.
47. Okuyama Y, Ishiguro H, Toru M, Arinami T. A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia. Biochem Biophys Res Commun 1999; 258: 292-295.
48. Mitsuyasu H, Hirata N, Sakai Y, Shibata H, Takeda Y, Ninomiya H et al Association analysis of polymorphisms in the upstream region of the human dopamine D4 receptor gene (DRD4) with schizophrenia and personality traits. J Hum Genet 2001; 46: 26-31.
49. Mitsuyasu H, Kawasaki H, Ninomiya H, Kinukawa N, Yamanaka T, Tahira T et al. Genetic structure of the dopamine receptor D4 gene (DRD4) and lack of association with schizophrenia in Japanese patients. J Psychiatr Res 2006 [Epub ahead of print].
50. Comings DE, Blum K. Reward deficiency syndrome: Genetic aspects of behavioral disorders. Prog Brain Res 2000; 126: 325-341.
51. ICRF. Effectiveness of a nicotine patch in helping people stop smoking: results of a randomised trial in general practice. Imperial Cancer Research Fund General Practice Research Group. BMJ 1993; 306 1304-1308.
52. ICRF. Randomised trial of nicotine patches in general practice: Results at one year. Imperial Cancer Research Fund General Practice Research Group. BMJ 1994; 308: 1476-1477.
53. Robinson TE, Berridge KC. The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Res Brain Res Rev 1993; 18: 247-291.
54. Hutchison KE, LaChance H, Niaura R, Bryan A, Smolen A. The DRD4 VNTR polymorphism influences reactivity to smoking cues.J Abnorm Psychol 2002; 111: 134-143.
55. Hutchison KE, McGeary J, Smolen A, Bryan A, Swift RM. The DRD4 VNTR polymorphism moderates craving after alcohol consumption. Health Psychol 2002; 21: 139-146.
56. Shao C, Li Y, Jiang K, Zhang D, Xu Y, Lin L et al. Dopamine D4 receptor polymorphism modulates cue-elicited heroin craving in Chinese. Psychopharmacology (Berlin) 2006; 186: 185-190.
57. Sobik L, Hutchison K, Craighead L. Cue-elicited craving for food: A fresh approach to the study of binge eating. Appetite 2005; 44 253-261.
58. Durston S, Fossella JA, Casey BJ, Hulshoff Pol HE, Galvan A, Schnack HG et al. Differential effects of DRD4 and DAT1 genotype on fronto-striatal gray matter volumes in a sample of subjects with attention deficit hyperactivity disorder, their unaffected siblings, and controls. Mol Psychiatry 2005; 10: 678-685.
59. Brody AL, Olmstead RE, London ED, Farahi J, Meyer JH, Grossman P et al. Smoking-induced ventral striatum dopamine release. Am J Psychiatry 2004; 161: 1211-1218.
60. David SP, Munafo MR, Johansen-Berg H, Smith SM, Rogers RD, Matthews PM et al. Ventral striaturn/nucleus accumbens activation to smoking-related pictorial cues in smokers and nonsmokers: A functional magnetic resonance imaging study. Biol Psychiatry 2005; 58: 488-494.
61. Goldstein RZ, Volkow ND. Drug addiction and its underlying neurobiological basis: Neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 2002; 159: 1642-1652.
62. McClemon FJ, Hiott FB, Huettel SA, Rose JE. Abstinence-induced changes in self-report craving correlate with event-related FMRI responses to smoking cues. Neuropsychopharmacology 2005; 10: 1940-1947.
63. Robinson TE, Berridge KC. Incentive-sensitization and addiction. Addiction 2001; 96: 103-114.
64. Yudkin P, Hey K, Roberts S, Welch S, Murphy K Walton R. Abstinence from smoking eight years after participation in randomised controlled trial of nicotine patch. BMJ 2003; 327: 28-29.
65. Lichter JB, Barr CL, Kennedy JL, Van Tol HH, Kidd KK, Livak KJ. A hypervariable segment in the human dopamine receptor D4 (DRD4) gene. Hum Mol Genet 1993; 2: 767-773.
66. Ronai Z, Barta C, Guttman A, Lakatos K, Gervai J, Staub M et al. Genotyping the -521C/T functional polymorphism in the promoter region of dopamine D4 receptor (DRD4) gene. Electrophoresis 2001; 22: 1102-1105.